In Situ Hybridization Market

Global In Situ Hybridization Market Size (2024 to 2029)

The size of the global in situ hybridization market is estimated to be worth USD 972.4 million by 2029 from USD 735.2 million in 2024, growing at a CAGR of 5.75% from 2024 to 2029. The market is expected to showcase an evident potential in the forecasted period. The market continues to gain momentum with rapid development in the medical industry. 

In situ hybridization (ISH) is a hybridization that involves a labeled complementary DNA, RNA, or modified nucleic acids strand to spot or localize a specific DNA or RNA sequence in a portion or part of the tissue, i.e., in situ. The effective techniques presently include in situ hybridization to mRNA with oligonucleotide and RNA probes; analysis with light and electron microscopes; whole mount in situ hybridization; double detection of RNAs and RNA plus protein; and fluorescent in situ hybridization to spot chromosomal sequences.

MARKET DRIVERS

Y-O-Y growth in cancer prevalence and rapidly increasing aging population are contributing to the growth of the in situ hybridization market.

The growing demand for precision diagnostic tests is expected to accelerate the global in situ hybridization market during the forecast period. ISH can detect cancer mutations, carcinogenic genes, and rare genetic disorders such as acute lymphoblastic leukemia, chronic myeloid leukemia, Down syndrome, and others. The incidence and prevalence of cancer and genetic diseases are increasing at a high rate, thus promoting the growth of the ISH in the global market. According to the National Cancer Institute statistics, cancer caused 9.5 million deaths in 2018; around one in six deaths is caused by cancer. In addition, there were 19 million new cases in 2018. It is estimated that cancer incidence could reach 32 million, with a death rate of 18 million in 2040. The growth of ancillary diagnostics has contributed to the increased demand for ISH technologies, especially anti-cancer drugs. 

Technological advancements are further accelerating the growth rate of the global ISH market.

Technological developments such as chromogenic in situ hybridization and fluorescent in situ hybridization, which is used to classify the role of genes that provide helpful information about tumors, are estimated to add significant growth during the forecast period. In addition, extensive studies and regulators worldwide have worked together to discover, develop, and implement next-generation diagnostic procedures that can gather information on physiological processes and disease pathogenesis are estimated to favor market growth during the forecast period.

In situ hybridization is a powerful technique for distinguishing different mRNA species within individual cells in tissue parts. Direct imaging of gene expression at the cellular level provides unique insight into the interaction between cancer cells and the tumor microenvironment as cancer progresses. In addition, there has been a recent increase in interest among patients and healthcare professionals in exploring the importance and acceptability of complementary diagnostics and personalized medicines. All these factors are anticipated to accelerate the growth rate of the global in situ hybridization market during the forecast period.

MARKET RESTRAINTS

Factors such as the high cost of in-situ hybridization, the need for skillful labor, and poor healthcare infrastructure are expected to negatively impact the global in situ hybridization market during the forecast period.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global In Situ Hybridization Market Analysis By Product

The probes and kits had the largest share in 2023 in the global in situ hybridization market and are expected to grow healthy during the forecast period. The growing use of reagents in research and diagnostic devices is a significant factor responsible for this segment's high growth rate. Another major factor contributing to the growth rate is the need for reliable, specific, and rapid detection of cancer and genetic disorders in the early stages.

The instruments segment is expected to register a reasonable growth rate during the forecast period as the adaptation of this technique increases among medical companies and there is a rise in the growth of infectious disease and cancer-related problems.

Global In Situ Hybridization Market Analysis By Technique

The fluorescent in-situ hybridization (FISH) segment held the largest share of the global ISH market in 2023 and is predicted to continue its dominance throughout the forecast period owing to the factors such as the high resolution of this technique, increasing adoption of research activities and laboratories for the diagnosis of cancer, chromosomal abnormalities, and infectious diseases among others.

On the other hand, the CISH segment is also expected to grow at a promising rate during the forecast period, mainly due to increased cancer cases worldwide and the spread of other infectious diseases.

Global In Situ Hybridization Market Analysis By Application

The cancer diagnosis segment is anticipated to grow rapidly during the forecast period. It is likely to contribute significantly during the forecast period due to the increasing prevalence of cancer, the increased adoption of FISH in cancer diagnosis, and the growing demand for FISH-based diagnostics.

The neuroscience segment is expected to grow at a prominent CAGR during the forecast period. The main reason for this growth is the increased adaptation of this technology and the increasing number of neuroscience problem cases.

The cytology and infectious Disease segments are also forecasted to rise as this technique becomes more popular and thus cheaper.

Global In Situ Hybridization Market Analysis By End-User

The molecular diagnostic laboratories segment was the market leader in 2023. It is also anticipated to grow at the highest CAGR during the forecast period due to the availability of expertise in molecular diagnostic laboratories for the FISH technique, the increased prevalence of cancer associated with genetic abnormalities, and the increased adoption of FISH in diagnosing cancer and genetic abnormalities.

REGIONAL ANALYSIS

The global market was dominated by North America in 2023, accounting for a significant share, followed by Europe.  The region's increasing incidence of cancer and infectious diseases focuses on developing personalized medicine and diagnostics tests, thus contributing largely to such growth rates. The strong demand for early cancer detection capabilities has ensured that ISH-based markets register steady growth during the forecast period. Research laboratories and academic institutes with modern facilities have helped develop this market and contributed to the development.

Europe had the second-largest share in 2023 in the global market. The primary factor is the rise in the geriatric population and the development of a quality healthcare system worldwide. In addition, the rising government initiatives have further boosted the regional market. The presence of skilled professionals will also help increase regional market revenue and growth.

In 2023, the UK accounted for most of the Europe ISH market share. The growing incidence of cancer and infectious diseases in the region emphasizes the development of personalized diagnostic and medical tests. There are around 385,000 new cancer cases in the UK annually, or approximately 1,100 every day, and over 185,000 new cancer cases among British women yearly. In addition, there are around 195,000 new cancer cases among British men each year. Additionally, improvement in the use of DNA probe-based diagnostics to identify diseases thought to be triggered by viruses and bacteria and the increasing prevalence of genetic disorders, schizophrenia, and other syndromes are expected to drive demand in this region during the forecast period.

The German ISH market is estimated to grow at a promising rate during the forecast period. The increasing demand for ISH techniques for the detection and treatment of various cancers and the rising cancer rate will facilitate the growth of the German in situ hybridization market during the forecast period. The highest cancer rate for both men and women was recorded in Germany, with 408 people per 100,000. Cancer awareness, advancements in medical facilities in cancer treatment, and increased government initiatives are other vital factors expected to affect the market's growth during the forecast periods. In addition, the region is home to a large base of clinical research laboratories and university institutes.

The Asia-Pacific is expected to register the highest growth among all other regions during the forecast period. Emerging markets such as India and China offer significant growth opportunities for MDx-based technology (including ISH) owing to the rising geriatric population and the growing prevalence of infectious diseases in these countries. The development of healthcare facilities has also improved this market. Increasing investments by respective government bodies and leading players in these countries ensures that the growth rate and revenue will increase.

Latin America is predicted to rise at a healthy CAGR during the forecast period. Combined, Brazil and Mexico are expected to occupy a significant share of the Latin American market during the forecast period.

The MEA is expected to grow at a steady CAGR during the forecast period.

KEY PLAYERS IN THE GLOBAL IN SITU HYBRIDIZATION MARKET

Some of the companies playing a crucial role in the Global In Situ Hybridization Market profiled in this report are Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.).

RECENT HAPPENINGS IN THE MARKET

• Ventana Medical System introduced an "INFORM HER2 SISH DNA Probe" analysis exclusively in the United States to detect the HER2 gene in breast cancer patients. SISH is a fully automated method for diagnosing prenatal cancer, which saves time by providing faster and more consistent results in clinical trials. 

• In May 2018, Lunaphore Technologies SA, a next-generation tissue diagnostics company, and Vitro SA, a manufacturer in the field of pathology and biomedical research, collaborated to develop In-Situ Hybridization (ISH) protocols for RNA and DNA targets in tissue using reagents provided by Vitro on Lunaphore’s rapid auto-staining platform. ISH hybridization techniques require protocols with a long overnight incubation period, challenging protocol automation. The collaboration aims to ease the development of ISH applications for Lunaphore’s platform with shorter turnaround times using one of the latest automation technologies.

DETAILED SEGMENTATION OF THE GLOBAL IN SITU HYBRIDIZATION MARKET INCLUDED IN THIS REPORT

This research report on the global in situ hybridization market has been segmented and sub-segmented based on type, product, technique, application, end user, and region.

By Technique

• FISH

• CISH

By Application

• Cancer Diagnosis

• Neuroscience

• Cytology

• Infectious Disease

By End User

• Molecular Diagnostic Laboratories

• Academic and Research Institutions

By Type

• DNA

• RNA

By Product

• Instruments

• Probes & Kits

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• The Middle East and Africa